达可替尼-话题@MedSci

#达可替尼#

7篇内容 | 1223人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2280056, encodeId=163b228005621, content=<a href='/topic/show?id=211e823029d' target=_blank style='color:#2F92EE;'>#肺腺癌#</a> <a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=首例：EGFR G719X突变不可切除IIIA期肺腺癌，新辅助化疗+达可替尼获根治性手术机会，PFS超14个月, objectType=article, longId=895334, objectId=e068895334e1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716044161853_5579292.jpg, objectUrl=/article/show_article.do?id=e068895334e1, replyNumber=0, likeNumber=12, createdTime=2025-09-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e068895334e1, moduleTitle=首例：EGFR G719X突变不可切除IIIA期肺腺癌，新辅助化疗+达可替尼获根治性手术机会，PFS超14个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e068895334e1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1952954, encodeId=2d69195295465, content=<a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, objectType=article, longId=727665, objectId=42bae2766592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42bae2766592, replyNumber=0, likeNumber=94, createdTime=2022-12-04, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42bae2766592, moduleTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42bae2766592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952952, encodeId=104f195295226, content=<a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=98, createdTime=2022-05-15, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952953, encodeId=c04f19529533b, content=<a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=220889, objectId=d4ae2208892d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ae2208892d, replyNumber=0, likeNumber=113, createdTime=2022-09-21, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ae2208892d, moduleTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ae2208892d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952950, encodeId=175a19529502b, content=<a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=王慧娟教授：达可替尼优势明显，一线治疗方案选择需考虑多重因素, objectType=article, longId=190282, objectId=410b19028294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=410b19028294, replyNumber=0, likeNumber=87, createdTime=2020-06-04, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=410b19028294, moduleTitle=王慧娟教授：达可替尼优势明显，一线治疗方案选择需考虑多重因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=410b19028294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952951, encodeId=118c1952951ff, content=<a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=赵明芳教授：达可替尼有望助力患者实现高质量长期生存, objectType=article, longId=194407, objectId=af8f19440ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af8f19440ecd, replyNumber=0, likeNumber=92, createdTime=2020-12-24, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af8f19440ecd, moduleTitle=赵明芳教授：达可替尼有望助力患者实现高质量长期生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af8f19440ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952949, encodeId=de3f195294940, content=<a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=ESMO Asia|达可替尼大大改善OS，亚裔和21 L858R突变患者均显著获益, objectType=article, longId=183915, objectId=0fd9183915be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fd9183915be, replyNumber=0, likeNumber=95, createdTime=2020-10-31, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fd9183915be, moduleTitle=ESMO Asia|达可替尼大大改善OS，亚裔和21 L858R突变患者均显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fd9183915be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952948, encodeId=0b121952948be, content=<a href='/topic/show?id=be679392124' target=_blank style='color:#2F92EE;'>#达可替尼#</a>, objectTitle=OS获益-陆舜教授谈达可替尼上市对EGFR突变晚期NSCLC全程管理影响, objectType=article, longId=168977, objectId=a9471689e7c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9471689e7c2, replyNumber=0, likeNumber=83, createdTime=2020-02-09, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9471689e7c2, moduleTitle=OS获益-陆舜教授谈达可替尼上市对EGFR突变晚期NSCLC全程管理影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9471689e7c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达可替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺腺癌# #达可替尼#

首例：EGFR G719X突变不可切除IIIA期肺腺癌，新辅助化疗+达可替尼获根治性手术机会，PFS超14个月

2025-09-04发表于上海

仁医06 (审核中...)

前往app查看评论内容

#达可替尼#

Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效

2022-12-04

海豹 (审核中...)

前往app查看评论内容

#达可替尼#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2022-05-15

海豹 (审核中...)

前往app查看评论内容

#达可替尼#

Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效

2022-09-21

海豹 (审核中...)

前往app查看评论内容

#达可替尼#

王慧娟教授：达可替尼优势明显，一线治疗方案选择需考虑多重因素

2020-06-04

海豹 (审核中...)

前往app查看评论内容

#达可替尼#

赵明芳教授：达可替尼有望助力患者实现高质量长期生存

2020-12-24

海豹 (审核中...)

前往app查看评论内容

#达可替尼#

ESMO Asia|达可替尼大大改善OS，亚裔和21 L858R突变患者均显著获益

2020-10-31

海豹 (审核中...)

前往app查看评论内容

#达可替尼#

OS获益-陆舜教授谈达可替尼上市对EGFR突变晚期NSCLC全程管理影响

2020-02-09

科室
- - 订阅+
  - 更多科室
工具
服务